On behalf of the ASTCT Committee on Education, we are pleased to continue our monthly self-directed learning quiz "Basic Principles and Practices of Hematopoietic Cell Transplantation and Cell Therapy – Question and Answer Approach” for fellows in training, highlighting HCT and cell therapy topics. Answers to each question appear with evidence-based “non-exhaustive” peer-review commentary. Our aim is to provide you with a credible and freely available educational resource. Questions generated and reviewed by Syed Abutalib, MD, Amrita Krishnan, MD, and William A. Wood, MD.

Question Title

* 1. According to expert opinion (2019) from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT; now American Society of Transplantation and Cellular Therapy [ASTCT])1 which of the following statements about exposure of inotuzumab ozogamicin prior to lymphodepleting therapy and tisagenlecleucel infusion is CORRECT?

Question Title

* 2. ELIANA trial3 - Tisagenlecleucel in children and young adults with B-cell acute lymphoblastic leukemia: What proportion of patients developed cytokine release syndrome (Penn grading system)?

Question Title

* 3. ELIANA trial3 - Tisagenlecleucel in children and young adults with B-cell acute lymphoblastic leukemia: What proportion of patients received tocilizumab for cytokine release syndrome (Penn grading system4)?

Question Title

* 4. ELIANA trial3 - Tisagenlecleucel in children and young adults with B-cell acute lymphoblastic leukemia: What are the risk factors for cytokine release syndrome?

Question Title

* 5. What is the first sign of cytokine release syndrome in patients treated with tisagenlecleucel?

T